10-Q: OraSure Reports Steep Revenue Decline, Widened Loss

OraSure Technologies, Inc. reported a significant decrease in net revenues and a substantial increase in net loss for the second quarter and first half of 2025, driven by reduced COVID-19 testing demand and strategic business exits.

Summary

• Net revenues for the three months ended June 30, 2025, decreased by 43% to $31.2 million from $54.3 million in the prior year period.
• Net revenues for the six months ended June 30, 2025, decreased by 44% to $61.2 million from $108.5 million in the prior year period.
• Net loss for the three months ended June 30, 2025, was $19.7 million, a significant increase from a net loss of $0.6 million in the same period last year.
• Net loss for the six months ended June 30, 2025, was $35.7 million, compared to a net loss of $4.2 million in the prior year period.
• Loss per share for the three months ended June 30, 2025, was $0.26, up from $0.01 in the prior year.
• Loss per share for the six months ended June 30, 2025, was $0.48, up from $0.06 in the prior year.
• Gross profit margin decreased to 42.1% for the three months ended June 30, 2025, from 45.4% in the prior year, primarily due to negative product mix.
• Gross profit margin decreased to 41.6% for the six months ended June 30, 2025, from 44.9% in the prior year.
• Research and development expenses increased by 73% to $11.4 million for the three months ended June 30, 2025, due to clinical trials for the Chlamydia Trachomatis (CT) and Neisseria Gonorrhoeae (NG) device and expenses from the Sherlock acquisition.
• Net cash used in operating activities for the six months ended June 30, 2025, was $30.0 million, a shift from $14.6 million provided by operating activities in the prior year.
• Cash and cash equivalents decreased to $234.6 million at June 30, 2025, from $267.8 million at December 31, 2024.
• Working capital decreased to $259.1 million at June 30, 2025, from $299.7 million at December 31, 2024.
• The company repurchased 1.8 million shares of its common stock under a $40.0 million stock repurchase program authorized in March 2025.

Sentiment

Score: 3

Explanation: The sentiment is negative due to substantial declines in revenue and significant increases in net and operating losses. While strategic shifts are underway to exit unprofitable segments and invest in new growth areas, the immediate financial performance is very weak, and cash flow from operations has turned negative. The stock repurchase program offers some positive signal, but it's overshadowed by the poor financial results.

Positives

• Diagnostics product revenues increased by 3% for the three months and 5% for the six months ended June 30, 2025, driven by higher international HIV and HCV revenues and new syphilis product sales.
• Non-product and services revenues increased significantly by 261% for the three months and 215% for the six months ended June 30, 2025, primarily due to funded R&D contracts from the Sherlock acquisition and BARDA contracts.
• The company is strategically exiting unprofitable business lines, including COVID-19 Diagnostics, Risk Assessment Testing, and Molecular Services, which is expected to streamline operations and improve future margins.
• Sales and marketing expenses decreased by 20% for the three months and 19% for the six months ended June 30, 2025, due to reduced employee costs, consulting fees, and bad debt expense.
• Improved overhead absorption partially offset negative impacts to gross margins as the company brings more production in-house to its Opus Way facility.
• A stock repurchase program of up to $40.0 million was authorized, with $5.0 million already used for repurchases, indicating management's confidence in the company's valuation.

Negatives

• Overall net revenues decreased significantly by 43% for the three months and 44% for the six months ended June 30, 2025, compared to the prior year periods.
• Net loss widened substantially to $19.7 million for the three months and $35.7 million for the six months ended June 30, 2025, from $0.6 million and $4.2 million respectively in the prior year periods.
• Gross profit margin declined due to a negative product mix, lower sales of high-margin InteliSwab and genomics products, and higher international product sales which generate lower margins.
• COVID-19 Diagnostics revenues decreased by 100% for the three months and 99% for the six months ended June 30, 2025, due to decreased demand and fulfillment of U.S. government contracts.
• Sample Management Solutions revenues decreased by 22% for the three months and 19% for the six months ended June 30, 2025, impacted by a large customer's bankruptcy proceedings and economic pressures.
• Risk Assessment Testing and Molecular Services revenues decreased by 81% and 100% respectively for the three months, and 57% and 100% respectively for the six months ended June 30, 2025, due to the discontinuance of these business lines.
• Operating loss increased significantly to $18.0 million for the three months and $35.8 million for the six months ended June 30, 2025.
• Cash and cash equivalents decreased by $33.2 million for the six months ended June 30, 2025, primarily due to negative cash flow from operating activities and stock repurchases.
• General and administrative expenses increased by 7% for the three months and 14% for the six months ended June 30, 2025, due to higher legal and accounting fees and costs associated with the Sherlock acquisition.
• Income tax expense increased due to recording an uncertain tax position for certain tax matters, including penalties and interest.

Risks

• Market acceptance of, and the company's ability to market and sell, its products and services.
• Failure of distributors or other customers to meet purchase forecasts, historic purchase levels, or minimum purchase requirements.
• Significant customer concentrations that exist or may develop in the future.
• Ability to manufacture products in accordance with applicable specifications, performance standards, and quality requirements.
• Ability to obtain, and timing and cost of obtaining, necessary regulatory approvals for new products or new indications/applications for existing products, and compliance with applicable regulatory requirements.
• Ability to effectively resolve warning letters, audit observations, and other findings or comments from the U.S. Food and Drug Administration (FDA) or other regulators.
• Changes in relationships, including disputes or disagreements, with strategic partners or other parties and reliance on strategic partners for critical activities.
• Ability to meet increased demand for its products.
• Impact of replacing distributors on the company's business.
• Inventory levels at distributors and other customers.
• Ability to achieve financial and strategic objectives and continue to increase revenues, including expanding international sales.
• Impact of competitors, competing products, and technology changes on the company's business.
• Reduction or deferral of public funding available to customers.
• Competition from new or better technology or lower cost products.
• Ability to develop, commercialize, and market new products.
• Changes in market acceptance of products based on product performance or other factors, including changes in testing guidelines, algorithms, or recommendations by the CDC or other agencies.
• Ability to fund research and development and other products and operations.
• Ability to obtain and maintain new or existing product distribution channels.
• Reliance on sole supply sources for critical products and components.
• Availability of related products produced by third parties or products required for use of the company's products.
• Impact of contracting with the U.S. government on the company's business.
• Impact of negative economic conditions on the company's business.
• Ability to achieve and maintain sustained profitability.
• Ability to increase gross margins.
• Ability to utilize net operating loss carry forwards or other deferred tax assets.
• Volatility of the company's stock price.
• Uncertainty relating to patent protection and potential patent infringement claims.
• Uncertainty and costs of litigation relating to patents, trade secrets, and other intellectual property.
• Availability of licenses to patents or other technology.
• Ability to enter into international manufacturing agreements.
• Obstacles to international marketing and manufacturing of products.
• Impact of changes in international funding sources and testing algorithms on international sales.
• Adverse movements in foreign currency exchange rates.
• Loss or impairment of sources of capital.
• Ability to attract and retain qualified personnel.
• Exposure to product liability and other types of litigation.
• Changes in international, federal, or state laws and regulations.
• Customer consolidations and inventory practices.
• Equipment failures and ability to obtain needed raw materials and components.
• Impact of terrorist attacks and civil unrest, hostilities, and war.
• Impact of cybersecurity incidents and other disruptions involving computer systems or those of third-party IT service providers, suppliers, and customers.
• General political, business, and economic conditions, including interest rates, inflationary pressures, capital market disruptions, changes in governmental agencies, international tariffs, trade protection measures, economic sanctions, and economic slowdowns or recession.
• Changes in tax laws or in their implementation or interpretation may adversely affect the company or its investors, including recent legislation like the One Big Beautiful Bill Act (OBBBA).

Future Outlook

The company expects the current level of COVID-19 Diagnostics revenue to continue throughout the remainder of 2025 and for the foreseeable future due to the fulfillment of existing contracts and lower overall demand. The Sherlock acquisition's first test for Chlamydia Trachomatis (CT) and Neisseria Gonorrhoeae (NG) is in clinical studies and is expected to be submitted to the FDA for approval by the end of 2025. The company expects its existing cash and cash equivalents to be sufficient to fund operating expenses and capital expenditure requirements over the next twelve months.

Management Comments

• The increase in income tax expense is largely due to recording an uncertain tax position for certain tax matters, including penalties and interest.
• The full valuation allowance established against total U.S. deferred tax asset is appropriate as the facts and circumstances necessitating the allowance have not changed.
• The company is currently evaluating the impacts of the One Big Beautiful Bill Act (OBBBA) but does not believe that changes in tax law will materially affect operating performance or financial position.
• The company's cash requirements may vary materially from those now planned due to factors such as strategic acquisitions, R&D progress, clinical testing costs, litigation, capital expenditures, business partner relationships, regulatory approvals, stock purchases, patent costs, sales and marketing expansion, market acceptance, competing developments, economic environment, and other factors.

Industry Context

The significant decline in COVID-19 Diagnostics revenue reflects a broader industry trend of decreased demand for COVID-19 testing as the pandemic shifts to an endemic phase. The company's strategic shift away from this and other non-core or declining businesses (Risk Assessment, Molecular Services) and its investment in new diagnostic areas like sexually transmitted infections (via Sherlock acquisition) and broader sample management solutions (via Sapphiros investment) indicate an adaptation to evolving market needs and a focus on higher-growth, more sustainable segments within the diagnostics and life sciences industry.

Comparison to Industry Standards

• NA

Corporate Governance

Legal Proceedings

• The company filed a complaint on November 14, 2024, against NowDiagnostics, Inc. (NowDx), Jody Berry, and Janean Young in the U.S. District Court for the Eastern District of Pennsylvania. Allegations include misappropriation and misuse of proprietary information and trade secrets, breach of contract, unfair competition, and tortious interference.
• NowDx filed Counterclaims on January 13, 2025, and the company filed its Answer on February 3, 2025.
• Young's Motion to Dismiss was denied by the court on February 4, 2025.
• NowDx, Berry, and Young agreed to a preliminary injunction, which the Court entered on February 27, 2025.
• The trial for this litigation is scheduled for March 9, 2026.

Stakeholder Impact

• **Shareholders**: Experience significant net losses and a decline in cash and working capital, potentially impacting share price. The stock repurchase program may offer some support but also uses cash. The long-term impact depends on the success of strategic shifts and new product development.
• **Employees**: Affected by past and ongoing workforce reductions (Q1 2024, Q2 2024, Q3 2024) as the company consolidates operations and exits certain business lines. New hires may occur in growth areas like R&D for new diagnostics.
• **Customers**: Those relying on discontinued product lines (COVID-19 Diagnostics, Risk Assessment Testing, Molecular Services) will need to find alternative solutions. Customers for Diagnostics (HIV, HCV, Syphilis) and Sample Management Solutions may see continued product availability and potential new offerings from the Sherlock acquisition.
• **Suppliers**: Those providing critical components or manufacturing services for discontinued lines may see reduced business. Suppliers for new product development and in-house manufacturing may see increased demand.
• **Creditors**: The company maintains a strong cash position ($234.6 million) and no significant changes to contractual obligations were noted, suggesting continued ability to meet short-term liabilities.

Next Steps

• Complete the consolidation of the Novosanis site in Belgium into other locations by the end of December 31, 2024 (already in progress).
• Complete the discontinuance of the Diversigen molecular services line of business by the end of June 30, 2024 (already completed).
• Complete the consolidation of facilities by bringing third-party manufacturing activities into Pennsylvania facilities by the end of the third quarter of 2025.
• Complete the Q3 2024 reduction in workforce related to discontinuing the risk assessment business by the third quarter of 2026.
• Submit Sherlock's first test for Chlamydia Trachomatis (CT) and Neisseria Gonorrhoeae (NG) to the FDA for approval by the end of 2025.
• Continue to operate under the stock repurchase program, which allows for purchases of up to $40.0 million in shares of common stock over a period of up to two years from March 21, 2025.
• Continue to evaluate the fair value of certain assets acquired and liabilities assumed from the Sherlock acquisition, with determination expected to be completed within one year from the acquisition date (December 19, 2024).

Key Dates

Recommendation

While the financial results for Q2 and H1 2025 show a substantial decline in revenue and a significant increase in net loss, the company is undergoing a strategic transformation. It is actively exiting unprofitable and declining business segments (COVID-19, Risk Assessment, Molecular Services) and investing heavily in new growth areas, particularly through the Sherlock Biosciences acquisition for new diagnostic tests and the Sapphiros partnership for sample management solutions. The increased R&D spend reflects this investment in future products. The stock repurchase program also indicates management's belief in the company's intrinsic value. For existing investors, holding the stock allows time for these strategic initiatives to potentially yield positive results and for the company to return to profitability. For new investors, the current financial performance presents a high-risk, high-reward scenario, making a 'hold' a cautious stance to observe the execution of the strategic pivot.

Keywords

Diagnostics, Sample Management, HIV Testing, HCV Testing, Sexually Transmitted Infections, Molecular Diagnostics, Biotechnology, Medical Devices, Clinical Trials, SEC Filing, 10-Q, Financial Results, Revenue Decline, Net Loss, Cash Flow, Stock Repurchase, Corporate Governance, Legal Proceedings